Suppressing stathmin-1 can inhibit chk1 protein expression and reduce the invasion and tumorigenicity of cervical cancer cells

The purpose of this study was to evaluate the effects of stathmin-1 on chk1 protein expression in cervical cancer cells and the influences on the cells’ invasion and tumorigenicity. Suppressed stathmin-1 expression in Hela cells and C33A cells by lentiviral vector were utilized. Real time PCR and Western blot were used to examine the expression of chk1. Cell proliferation and invasion were studied using MTT assays and transwell migration assays.The differences of tumorigenicity in vivo were explored using xenograft experiments. In addition, stathmin-1 expressions in 24 cervical cancer patients were studied without regional lymph nodes metastasis and 16 metastatic patients by immunohistochemistry assays and real time PCR. This study found downregulating stathmin-1 reduced chk1 expressions and the proliferation and invasion in cervical cancer cells and reduced the tumorigenicity of tumor cells.

Stathmin-1; chk1; Cervical cancer; Invasion; Tumorigenicity.

[1] Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer”. Expert Opin. Ther. Targets, 2011, 15, 1249.

[2] Bhagirath D., Abrol N., Khan R., Sharma M., Seth A., Sharma A.: “Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder”. Clin. Chim. Acta, 2012, 413, 1641.

[3] Han Z.X., Wang H.M., Jiang G., Du X.P., Gao X.Y., Pei D.S.: “Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2”. Cancer Biother. Radiopharm., 2013, 28, 398.

[4] Chen Y.L., Uen Y.H., Li C.F., Horng K.C., Chen L.R., Wu W.R., et al.: “The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma”. Ann. Surg. Oncol., 2013, 20, 4041.

[5] Miceli C., Tejada A., Castaneda A., Mistry S.J.: “Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer”. Cancer Gene Ther., 2013, 20, 298.

[6] Sonego M., Schiappacassi M., Lovisa S., Dall'Acqua A., Bagnoli M., Lovat F., et al.: “Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer”. EMBO Mol. Med., 2013, 5, 707.

[7] Kouzu Y., Uzawa K., Koike H., Saito K., Nakashima D., Higo M., et al.: “Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis”. Br. J. Cancer, 2006, 94, 717.

[8] Mistry S.J., Bank A., Atweh G.F.: “Targeting stathmin in prostate cancer”. Mol. Cancer Ther., 2005, 4, 1821.

[9] Jeon T.Y., Han M.E., Lee Y.W., Lee Y.S., Kim G.H., Song G.A., et al.: “Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells”. Br. J. Cancer, 2010, 102, 710.

[10] Castellsagué X.: “Natural history and epidemiology of HPV infection and cervical cancer”. Gynecol. Oncol., 2008, 110, S4.

[11] Feng Y.J., Shen K.: “Obstetrics and gynecology”. In: Li L. (ed). Female genital tumors. Beijing: People's Health Publishing House, 2011, 325.

[12] Xi W., Rui W., Fang L., Ke D., Ping G., Hui-Zhong Z.: “Expression of stathmin/op18 as a significant prognositic factor for cervical carcinoma patients”. J. Cancer Res. Clin. Oncol., 2009, 135, 837.

[13] Howitt B.E., Nucci M.R., Drapkin R., Crum C.P., Hirsch M.S.: “Stathmin-1 expression as a complement to p16 helps identify highgrade cervical intraepithelial neoplasia with increased specificity”. Am. J. Surg. Pathol., 2013, 37, 89.

[14] Carney B.K., Cassimeris L.: “Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and can¬cer cell lines lacking the tumor suppressor, p53”. Cancer Biol. Ther., 2010, 9, 699.

[15] Wu Y., Tang M., Wu Y., Weng X., Yang L., Xu W., et al.: “A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells”. Cell Oncol. (Dordr.), 2014, 37, 53.

[16] Larsson N., Marklund U., Gradin H.M., Brattsand G., Gullberg M.: “Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis”. Mol. Cell Biol., 1997, 17, 5530.

[17] Holmfeldt P., Sellin M.E., Gullberg M.: “Predominant regulators of tubu¬lin monomer-polymer partitioning and their implication for cell polarization”. Cell Mol. Life Sci., 2009, 66, 3263.

[18] Trovik J., Wik E., Stefansson I.M., Marcickiewicz J., Tingulstad S., Staff A.C., et al.: “Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer”. Clin. Cancer Res., 2011, 17, 3368.

[19] Salvesen H.B., Carter S.L., Mannelqvist M., Dutt A., Getz G., Stefansson I.M., et al.: “Integrated genomic profiling ofendometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation”. Proc. Natl. Acad. Sci. USA, 2009, 106, 4834.

[20] Kuo M.F., Wang H.S., Kuo Q.T., Shun C.T., Hsu H.C., Yang S.H., Yuan R.H.: “High expression of stathmin protein predicts a fulminant course inmedulloblastoma”. J. Neurosurg. Pediatr., 2009, 4, 74.

[21] Su D., Smith S.M., Preti M., Schwartz P., Rutherford T.J., Menato G., et al.: “Stathmin and tubulin expression and survival ofovarian cancer patients receiving platinum treatment with and withoutpaclitaxel”. Cancer, 2009, 115, 2453.

[22] Kouzu Y., Uzawa K., Koike H., Saito K., Nakashima D., Higo M., et al.: “Overexpression of stathmin in oralsquamous-cell carcinoma: correlation with tumour progression and poorprognosis”. Br. J. Cancer, 2006, 94, 717.

[23] Akhtar J., Wang Z., Yu C., Li C.S., Shi Y.L., Liu H.J.: “STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells”. BMC Cancer, 2014, 14, 28.

[24] Wu Y., Tang M., Wu Y., Weng X., Yang L., Xu W., et al.: “A combination of paclitaxel and siRNA-mediated silencingof Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells”. Cell Oncol. (Dordr.), 2014, 37, 53.

[25] Xi W., Rui W., Fang L., Ke D., Ping G., Hui-Zhong Z.: “Expression of stathmin /op18 as a signiWcant prognostic factorfor cervical carcinoma patients”. J. Cancer Res. Clin. Oncol., 2009, 135, 837.

[26] Calvo A., Perez-Stable C., Segura V., Catena R., Guruceaga E., Nguewa P., et al.: “Molecular characterization of the Ggamma-globin- Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer”. Prostate, 2010, 70, 630.

[27] Carr J.R., Park H.J., Wang Z., Kiefer M.M., Raychaudhuri P.: “FoxM1 mediates resistance to herceptin and paclitaxel”. Cancer Res., 2010, 70, 5054.

[28] Johnsen J.I., Aurelio O.N., Kwaja Z., Jörgensen G.E., Pellegata N.S.: “p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest”. Int. J. Cancer, 2000, 88, 685.

[29] Silva V.C., Cassimeris L.: “Stathmin and microtubules regulate mitotic entry in Hela cells by controlling activation of both Aurora kinase A and Plk1”. Mol. Biol. Cell., 2013, 24, 3819.

[30] Cole K.A., Huggins J., Laquaglia M., Hulderman C.E., Russell M.R., Bosse K., et al.: “RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma”. Proc. Natl. Acad. Sci. USA, 2011, 108, 3336.

[31] Brooks K., Oakes V., Edwards B., Ranall M., Leo P., Pavey S., et al.: “A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress”. Oncogene, 2013, 32, 788.

[32] Wang Y., Decker S.J., Sebolt-Leopold J.: “Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis”. Cancer Biol. Ther., 2004, 3, 305.

[33] Tho L.M., Libertini S., Rampling R., Sansom O., Gillespie D.A.: “Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis”. Oncogene, 2012, 31, 1366.